Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Bladder Cancer

  Free Subscription


23.11.2026

1 ACS Nano
1 Aging (Albany NY)
1 Anal Chem
1 Ann Surg Oncol
1 Bioengineered
1 Biomaterials
3 BMC Cancer
3 BMC Urol
1 Cancer Discov
1 Cancer Immunol Immunother
1 Cancer Inform
2 Cancer Lett
1 Cancer Med
1 Cancers (Basel)
1 Cell Press Blue
1 Cell Signal
1 CJC Open
1 Clin Cancer Res
1 Clin Genitourin Cancer
1 Clin Med Insights Arthritis Musculoskelet Disord
1 Comput Methods Biomech Biomed Engin
1 Crit Rev Oncol Hematol
1 Diagnostics (Basel)
1 Environ Toxicol
3 Fr J Urol
1 Front Immunol
1 Gan To Kagaku Ryoho
1 Genes Dis
1 IJU Case Rep
1 Int J Mol Sci
1 Int J Urol
1 Int Urol Nephrol
1 J Am Vet Med Assoc
2 J Clin Med
1 JAMA Netw Open
1 Jpn J Clin Oncol
1 Lab Invest
1 Magn Reson Imaging Clin N Am
1 Med Oncol
1 Mol Biomed
3 N Engl J Med
1 Nat Commun
1 Oncol Lett
1 PLoS Negl Trop Dis
1 Radiol Imaging Cancer
1 Sci Rep
1 Sci Signal
1 Semin Oncol Nurs
1 Sichuan Da Xue Xue Bao Yi Xue Ban
1 Target Oncol
2 Ther Adv Urol
1 Tissue Eng Part B Rev
1 Urol Int
9 Urol Oncol
2 Urology
3 World J Surg Oncol
4 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    ACS Nano

  1. DONG H, Chen L, Teng X, Shi J, et al
    Disassembly of Extracellular Matrix and Intercellular Adhesion Enables Noninvasive Bladder Cancer Disaggregation.
    ACS Nano. 2026;20:31123-31136.
    PubMed         Abstract available


    Aging (Albany NY)

  2. YANG C, Li Q, Chen X, Zhang Z, et al
    Retraction of: Circular RNA circRGNEF promotes bladder cancer progression via miR-548/KIF2C axis regulation.
    Aging (Albany NY). 2026;18:1529.
    PubMed        


    Anal Chem

  3. WANG W, Xing Z, Wang B, Zheng S, et al
    A Self-Confined Rotational Hydrogel Chemiluminescence Motor Array for Rapid and Sensitive Detection of Bladder Cancer Biomarkers.
    Anal Chem. 2026;98:33328-33337.
    PubMed         Abstract available


    Ann Surg Oncol

  4. SU D, Li S, Hou J, Chen G, et al
    Preoperative Renal Impairment as an Independent Determinant of Poor Survival After Concomitant Laparoscopic Radical Cystectomy and Nephroureterectomy.
    Ann Surg Oncol. 2026;33:11644-11653.
    PubMed         Abstract available


    Bioengineered


  5. Statement of Retraction: Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.
    Bioengineered. 2026;17:2749381.
    PubMed        


    Biomaterials

  6. GAO M, Tian J, Guo H, Xu H, et al
    A urea-powered platelet micromotor initiates self-amplifying ECM remodeling to potentiate BCG immunotherapy in bladder cancer.
    Biomaterials. 2026;339:124784.
    PubMed         Abstract available


    BMC Cancer

  7. CAO S, Liu M, Wang C, Yang S, et al
    Nonsteroidal anti-inflammatory drug use and site-specific risk of urological cancers: a systematic review and meta-analysis.
    BMC Cancer. 2026;26:1471.
    PubMed         Abstract available

  8. ISHIMOTO K, Narita T, Sekine Y, Shinohara M, et al
    Real-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma.
    BMC Cancer. 2026;26:1470.
    PubMed         Abstract available

  9. PARVIZIFARA S, Angaji SA, Beikzadeh B, Narouie B, et al
    CD22 and CD79A expression level in bladder cancer patients using bioinformatics tools, RNA-Seq and qRT-PCR validation.
    BMC Cancer. 2026;26:1419.
    PubMed         Abstract available


    BMC Urol

  10. YAN Y, Wang L, Zhou Y, Wang X, et al
    Preoperative frailty and multidimensional concurrent correlates among older adults scheduled for radical cystectomy: a social ecological model-informed cross-sectional study.
    BMC Urol. 2026;26:295.
    PubMed         Abstract available

  11. CIN H, Gulmez H, Turan T
    Impact of pioglitazone use on clinicopathological features and aggressiveness of bladder cancer: a retrospective cohort study.
    BMC Urol. 2026;26:304.
    PubMed        

  12. DAMA M, Ahmadzada J, Efiloglu O, Bozkurt YE, et al
    The prognostic impact of variant histology timing in bladder cancer: a comparative analysis of primary and secondary detection.
    BMC Urol. 2026;26:300.
    PubMed         Abstract available


    Cancer Discov


  13. Cell-free RNA in Urine May Detect Bladder Cancer and Distinguish Response.
    Cancer Discov. 2026 Nov 20:OF1. doi: 10.1158/2159-8290.CD-RW2026.
    PubMed        


    Cancer Immunol Immunother

  14. KOYAMA Y, Takanashi M
    Targeting neutral sphingomyelinase enhances NK cell-mediated immunity via the CXCL10-CXCR3 axis in murine bladder cancer cells.
    Cancer Immunol Immunother. 2026;75:288.
    PubMed         Abstract available


    Cancer Inform

  15. KUMARI R, Bhushan A, Kaur J, Nagar PK, et al
    Identification of Immune-Associated Hub Genes Related to the G2/M Checkpoint Pathway in Bladder Cancer Through Integrated Bioinformatics Analysis.
    Cancer Inform. 2026;25:11769351261500680.
    PubMed         Abstract available


    Cancer Lett

  16. XU G, Zhao W, Li Y, Fang S, et al
    The HDAC2/KAT2A-Lamin A lactylation axis regulates tumor progression and chemoresistance in bladder cancer.
    Cancer Lett. 2026;664:218968.
    PubMed         Abstract available

  17. WU Y, Xu Z, Yin L, Wang R, et al
    Lactylation-driven NOP2 stabilization suppresses ferroptosis to promote cisplatin resistance via enhancing m5C-Dependent GLS1 mRNA stability in bladder cancer.
    Cancer Lett. 2026 Nov 19:218989. doi: 10.1016/j.canlet.2026.218989.
    PubMed         Abstract available


    Cancer Med

  18. GUO X, Ma Y, He L, Chen Y, et al
    Prognostic Significance of Adverse Histopathological Features in Early-Onset Bladder Urothelial Carcinoma After Radical Cystectomy: A Propensity Score-Matched Analysis.
    Cancer Med. 2026;15:e72500.
    PubMed         Abstract available


    Cancers (Basel)

  19. QIN SL, Owusu-Amo B, Miyamoto DT
    Revealing the Invisible: Circulating and Urinary Tumor DNA in Bladder Cancer.
    Cancers (Basel). 2026;18:3566.
    PubMed         Abstract available


    Cell Press Blue

  20. CARVALHO FLF, Lee J, Kalavros N, Zhou Y, et al
    Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer.
    Cell Press Blue. 2026;1:100100.
    PubMed         Abstract available


    Cell Signal

  21. ZHU J, Pan X, Zhang Z, Gao J, et al
    Retraction notice to "Downregulation of integrin-linked kinase inhibits epithelial-to-mesenchymal transition and metastasis in bladder cancer cells" [Cell. Signal. 24 (2012) 1323-1332].
    Cell Signal. 2026 Nov 18:112992. doi: 10.1016/j.cellsig.2026.112992.
    PubMed        


    CJC Open

  22. FUJIO K, Higaki A, Miura N, Kurokawa K, et al
    A Case of Confirmed Diagnosis of Wild-Type Transthyretin Cardiac Amyloidosis from a Bladder Cancer Resection Specimen.
    CJC Open. 2026;8:1526-1529.
    PubMed        


    Clin Cancer Res

  23. OSORIO JC, Blanchard L, Yao N, Alam SM, et al
    Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Phase I Trial.
    Clin Cancer Res. 2026 Nov 17. doi: 10.1158/1078-0432.CCR-26-3256.
    PubMed         Abstract available


    Clin Genitourin Cancer

  24. EKENCI BY, Sari H, Durak HM, Karakoyunlu AN, et al
    Histological Subtypes, Divergent Differentiation, and Neuroendocrine Components in Primary Non-Muscle-Invasive Bladder Cancer Managed with Bladder-Preserving Approaches: A Propensity Score-Matched Study.
    Clin Genitourin Cancer. 2026 Oct 26:102703. doi: 10.1016/j.clgc.2026.102703.
    PubMed         Abstract available


    Clin Med Insights Arthritis Musculoskelet Disord

  25. KUCUKSEN MF, Colak TS, Goger YE, Esen HH, et al
    Unusual Presentation of Metastatic Bladder Cancer: A Case Report of Acrometastasis to the Hand and Review of the Literature.
    Clin Med Insights Arthritis Musculoskelet Disord. 2026.
    PubMed         Abstract available


    Comput Methods Biomech Biomed Engin

  26. GU Y, Zhuo H
    Machine learning-driven construction and validation of an intra-tumoral heterogeneity-associated prognostic model for bladder urothelial carcinoma.
    Comput Methods Biomech Biomed Engin. 2026;29:3541-3553.
    PubMed         Abstract available


    Crit Rev Oncol Hematol

  27. GHALEHTAKI R, Shariati A, Mehrtabar E, Arshadi MR, et al
    Adding immune checkpoint inhibitors to bladder-preservation therapy in muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Crit Rev Oncol Hematol. 2026;229:105701.
    PubMed         Abstract available


    Diagnostics (Basel)

  28. EL BOUHADDANI S, Albashri A, Almohammadi O, Alamri M, et al
    From Stage to Systems: Integrating Standard Laboratory Markers into Bladder Cancer Prognostic Models.
    Diagnostics (Basel). 2026;16:3486.
    PubMed         Abstract available


    Environ Toxicol

  29. SAINI D, Chaudhary PK, Lhamu T, Chaudhary JK, et al
    Eugenol Suppresses Heavy Metal-Induced Proliferation of Urinary Bladder Cancer Cells Through Modulation of DNA Demethylation and Activation of the Intrinsic Apoptotic Pathway.
    Environ Toxicol. 2026 Nov 16. doi: 10.1002/tox.70209.
    PubMed         Abstract available


    Fr J Urol

  30. AZZOUZI ME, HafidiAlaoui C, Ahanidi HE, Imane C, et al
    TP53 Sequence Variant Profiling in Moroccan Patients with Non-Metastatic Bladder Cancer: Analysis of Exons 4-9.
    Fr J Urol. 2026 Nov 19:103290. doi: 10.1016/j.fjurol.2026.103290.
    PubMed         Abstract available

  31. ROUMIGUIE M, Marcq G, Bajeot AS, Allory Y, et al
    French AFU Cancer Committee Guidelines - Update 2026-2028: Muscle-invasive bladder tumors (MIBC).
    Fr J Urol. 2026;36:103192.
    PubMed         Abstract available

  32. ROUMIGUIE M, Pradere B, Bajeot AS, Leon P, et al
    French AFU Cancer Committee Guidelines - Update 2026-2028: Non-muscle-invasive bladder tumors (NMIBC).
    Fr J Urol. 2026;36:103182.
    PubMed         Abstract available


    Front Immunol

  33. LU P, Zhou L
    Cancer-associated fibroblasts and extracellular matrix remodeling driving drug resistance and immune evasion in bladder cancer: research progress.
    Front Immunol. 2026;17:1941274.
    PubMed         Abstract available


    Gan To Kagaku Ryoho

  34. NAGUMO Y, Kinase S, Nishiyama H
    [Recent Advances in ctDNA and utDNA Research for Bladder Cancer].
    Gan To Kagaku Ryoho. 2026;53:683-688.
    PubMed         Abstract available


    Genes Dis

  35. LUO Z, Xu D, Wang Z, Wu L, et al
    Charting the landscape of microbiota in bladder cancer: Molecular mechanisms and therapeutic implications.
    Genes Dis. 2026;14:102270.
    PubMed         Abstract available


    IJU Case Rep

  36. TAKAHASHI T, Takamatsu K, Igarashi D, Umezawa Y, et al
    Adrenal Insufficiency After Preoperative Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced Bladder Cancer: A Case Report.
    IJU Case Rep. 2026;9:e70292.
    PubMed         Abstract available


    Int J Mol Sci

  37. LAWINSKI J, Franczyk B, Sagr A, Popek K, et al
    Clinical Utility of lncRNAs in Urothelial Carcinoma of the Bladder: Diagnostics, Risk Stratification, and Treatment Guidance.
    Int J Mol Sci. 2026;27:9461.
    PubMed         Abstract available


    Int J Urol

  38. KAKITA S, Matsuo T, Otsubo A, Araki K, et al
    Phospho-LATS1/2 Immunoreactivity and Survival in Muscle-Invasive Bladder Cancer: A Quantitative Immunohistochemical Study.
    Int J Urol. 2026;33:e70715.
    PubMed         Abstract available


    Int Urol Nephrol

  39. JAABOU M, Dovey Z, Zaytoun O, Awan M, et al
    Predictors of residual tumour and recurrence in high-grade NMIBC: insights from a multicenter re-TURBT cohort.
    Int Urol Nephrol. 2026;58:5215-5221.
    PubMed         Abstract available


    J Am Vet Med Assoc

  40. DHAWAN D, Sola MF, Nelson JB, Lanman NA, et al
    BRAFV595E mutation detected across the disease spectrum from non-neoplastic urothelium to invasive urothelial carcinoma in dogs.
    J Am Vet Med Assoc. 2026;264.
    PubMed         Abstract available


    J Clin Med

  41. WONG J, Wong R, Hamilton Z, Wang L, et al
    Role of Radical Cystectomy in Metastatic Bladder Cancer.
    J Clin Med. 2026;15:8586.
    PubMed         Abstract available

  42. VASILE DF, Mesina M, Mitroi GG, Danila AD, et al
    Preoperative Systemic Inflammatory Indices (SII, SIRI and PIV) Associated with Adverse Histology and 12-Month Recurrence After Transurethral Resection of Non-Muscle-Invasive Bladder Cancer.
    J Clin Med. 2026;15:8536.
    PubMed         Abstract available


    JAMA Netw Open

  43. SINGH P, Plets M, Efsthathiou J, Jhavar SG, et al
    Study Rationale, Enrollment Characteristics, and Central Review of Clinical Stage: The INTACT Randomized Clinical Trial.
    JAMA Netw Open. 2026;9:e2644122.
    PubMed         Abstract available


    Jpn J Clin Oncol

  44. OKUMURA G, Yoshida S, Hirose K, Yajima S, et al
    A Bayesian reanalysis of the THOR trial cohort 1 using reconstructed individual patient data: interval-specific effects and clinically interpretable estimands under non-proportional hazards.
    Jpn J Clin Oncol. 2026;56:1437-1442.
    PubMed         Abstract available


    Lab Invest

  45. LEE SY, Jang S, Lee D, Jo D, et al
    Prognostic Significance of AI-Quantified Central Tumor-Infiltrating Lymphocytes in Bladder Cancer.
    Lab Invest. 2026 Nov 20:106183. doi: 10.1016/j.labinv.2026.106183.
    PubMed         Abstract available


    Magn Reson Imaging Clin N Am

  46. ROMSA J, Sutherland D, Akincioglu C
    MR Clinics-Nuclear Medicine in Renal, Adrenal, Bladder and Urothelial Malignancies.
    Magn Reson Imaging Clin N Am. 2027;35:63-77.
    PubMed         Abstract available


    Med Oncol

  47. ISKENDER B, Izgi K
    Evaluation of a KLH-conjugated uroplakin 3A-derived peptide formulation in an OH-BBN bladder cancer model.
    Med Oncol. 2026;43:388.
    PubMed         Abstract available


    Mol Biomed

  48. YANG M, Li R, Huang Z, Shao W, et al
    Tetrahydrocurcumin suppresses bladder cancer progression by modulating SPP1-associated M2 macrophage-tumor interaction.
    Mol Biomed. 2026;7:252.
    PubMed         Abstract available


    N Engl J Med

  49. TAKEMURA K, Miura Y, Kitano S
    Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer.
    N Engl J Med. 2026;395:2073.
    PubMed        

  50. KIKILI CI, Kemik F, Tural D
    Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer.
    N Engl J Med. 2026;395:2073-2074.
    PubMed        

  51. GALSKY MD
    Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer. Reply.
    N Engl J Med. 2026;395:2074-2075.
    PubMed        


    Nat Commun

  52. CHAIYADET S, Roblin T, Fauchois A, Temmam S, et al
    Fluke-borne viruses are a risk factor and diagnostic target for diseases caused by carcinogenic trematodes.
    Nat Commun. 2026;17:11707.
    PubMed         Abstract available


    Oncol Lett

  53. LI Z, Zhang TB, Jia DH, Sun WQ, et al
    [Retracted] Genipin inhibits the growth of human bladder cancer cells via inactivation of PI3K/Akt signaling.
    Oncol Lett. 2026;33:14.
    PubMed         Abstract available


    PLoS Negl Trop Dis

  54. GAYE O, Diallo K, Fall CB, Comperat E, et al
    Molecular mechanisms of Schistosoma haematobium-associated bladder carcinogenesis and urinary biomarkers for early diagnosis: A review.
    PLoS Negl Trop Dis. 2026;20:e0014868.
    PubMed         Abstract available


    Radiol Imaging Cancer

  55. SILIPIGNI S, Arillotta GM, Maccarrone E, Racchiusa S, et al
    Spectral CT for Assessing Local Tumor Invasion in Bladder Cancer.
    Radiol Imaging Cancer. 2026;8:e260451.
    PubMed        


    Sci Rep

  56. HUMAYUN-ZAKARIA N, Yu M, Goel A, Gordon NS, et al
    Transcriptomic profiling of tropomyosin isoforms in bladder cancer: multi-platform sequencing and experimental validation.
    Sci Rep. 2026;16:37672.
    PubMed         Abstract available


    Sci Signal

  57. GILLEY KN, Garness J, Khan A, Materia BR, et al
    Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity.
    Sci Signal. 2026;19:eaef1375.
    PubMed         Abstract available


    Semin Oncol Nurs

  58. WEI R, Guo Y, Jin D, Zhu HJ, et al
    Best Evidence for Bladder Function Exercise in Patients With Bladder Cancer Following Orthotopic Neobladder Reconstruction.
    Semin Oncol Nurs. 2026;43:152415.
    PubMed         Abstract available


    Sichuan Da Xue Xue Bao Yi Xue Ban

  59. LI S, Ding H, Bai Y, Liu H, et al
    [Predictive Performance of an Ultrasound Blood Perfusion Parameter-Based Model for Postoperative Prognosis of Patients With Bladder Cancer].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2026;57:1514-1520.
    PubMed         Abstract available


    Target Oncol

  60. MATSUKAWA A, Mori K, Yanagisawa T, Miyajima K, et al
    Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Network Meta-analysis.
    Target Oncol. 2026 Nov 18. doi: 10.1007/s11523-026-01270.
    PubMed         Abstract available


    Ther Adv Urol

  61. MANIVASAGAM SS, Sheikhsaran F, Raman JD, Aminsharifi A, et al
    Circulating tumor DNA as a tool for precision management in bladder cancer: A narrative review.
    Ther Adv Urol. 2026;18:17562872261493705.
    PubMed         Abstract available

  62. SIGVA H, Sevim M, Korpe K, Atis V, et al
    Machine learning-based prediction of BCG NON-RESPONSE in high-risk NON-muscle-invasive bladder cancer: An exploratory single-centre cohort study.
    Ther Adv Urol. 2026;18:17562872261493691.
    PubMed         Abstract available


    Tissue Eng Part B Rev

  63. HAN J, Li X, Zhou X, Zhang Y, et al
    Hydrogel-Based Therapies for Bladder Cancer: Intravesical Delivery, Immunomodulation, and Precision.
    Tissue Eng Part B Rev. 2026 Nov 18:19373368261506151.
    PubMed         Abstract available


    Urol Int

  64. TOPCU I, Ozdes AA, Dural B, Yildirim OF, et al
    The CALLY Index as an Independent Predictor of Survival in Bladder Cancer Patients Undergoing Radical Cystectomy: A Multicenter Study.
    Urol Int. 2026 Nov 16:aewag059. doi: 10.1159.
    PubMed         Abstract available


    Urol Oncol

  65. XU H, Bai Y
    Re: Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.
    Urol Oncol. 2026 Nov 20:S1078-1439(26)00775.
    PubMed        

  66. NOMINATO EO, Miranda AARR, Fernandes MEM, Amaral VL, et al
    Intraoperative indocyanine green fluorescence guidance to reduce ureteroenteric anastomotic strictures during robot-assisted radical cystectomy. A systematic review and meta-analysis.
    Urol Oncol. 2026;44:998-1006.
    PubMed         Abstract available

  67. TAN H, Zhang Y, Long Y, Shu L, et al
    CDKL1 facilitates tumorigenesis and metastasis of bladder urothelial carcinoma by activating SIRT1/Wnt/beta-catenin signaling.
    Urol Oncol. 2026;44:1007-1022.
    PubMed         Abstract available

  68. PEREZ-LONDONO A, Kaul S, Fleishman A, Konety B, et al
    Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy.
    Urol Oncol. 2026;44:1023-1032.
    PubMed         Abstract available

  69. ZHANG H, Lv Z, Wang Z, Lu Y, et al
    Postoperative progression-free survival and clinicopathological risk stratification in urachal carcinoma: A multicenter retrospective cohort study.
    Urol Oncol. 2026;44:887-896.
    PubMed         Abstract available

  70. BRIGGS LG, Choudry MM, Nguyen MV, Durant AM, et al
    Prehabilitation for patients undergoing radical cystectomy: Patient selection and targeted interventions.
    Urol Oncol. 2026;44:911-920.
    PubMed         Abstract available

  71. SHIMODA H, Numao N, Oki R, Urasaki T, et al
    Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma.
    Urol Oncol. 2026;44:931-938.
    PubMed         Abstract available

  72. CRONIN C, Wallace BK, Gumma ME, Weitzner AS, et al
    Is all gross hematuria high risk? Age-stratified outcomes after anticoagulation initiation using a large claims database.
    Urol Oncol. 2026;44:969-976.
    PubMed         Abstract available

  73. BI W, Xu L, Ma L, Zhu J, et al
    FOXP2/FABP4 axis promotes bladder cancer aggressiveness by driving lipid metabolic reprogramming to activate FAK/Src signaling.
    Urol Oncol. 2026 Nov 13:S1078-1439(26)00770.
    PubMed         Abstract available


    Urology

  74. TALLMAN JE, Hyman MJ, Agarwal PK, Faris SF, et al
    Reply to "Editorial Comment on "Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer.
    Urology. 2026 Nov 18:S0090-4295(26)00729-6. doi: 10.1016/j.urology.2026.
    PubMed        

  75. SOOD A
    Editorial Comment on "Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer".
    Urology. 2026 Nov 13:S0090-4295(26)00721-1. doi: 10.1016/j.urology.2026.
    PubMed        


    World J Surg Oncol

  76. LI W, Wu R, Fang P, Huang T, et al
    Decoding hypoxia-driven microenvironment remodeling in bladder cancer reveals TPST1 as a key driver of metastasis.
    World J Surg Oncol. 2026;24:439.
    PubMed         Abstract available

  77. WANG Y, Zhou X, Li J, Qu H, et al
    Does neoadjuvant or induction systemic therapy modify the association between pelvic lymph node dissection metrics and survival after radical cystectomy for bladder cancer? A systematic review and meta-analysis.
    World J Surg Oncol. 2026;24:427.
    PubMed         Abstract available

  78. LI Y, Yan Y, Zuo L, Dong X, et al
    Unlocking a TP53 mutation-specific vulnerability: the miR-486-3p/CYB561 axis in bladder cancer.
    World J Surg Oncol. 2026;24:434.
    PubMed         Abstract available


    World J Urol

  79. STOKKEL LE, Angelino M, Boellaard TN, van de Kamp MW, et al
    Detection of recurrence after surgical treatment for urachal adenocarcinoma: diagnostic yield of cystoscopy, imaging and serum tumor markers.
    World J Urol. 2026;44:803.
    PubMed         Abstract available

  80. IBRAHIM Y, Rajain S, Abu-Ghanem Y, Ribeiro L, et al
    Outcomes of robot-assisted cystectomy and intracorporeal ileal conduit diversion in radiotherapy-exposed patients: propensity-score matched analysis.
    World J Urol. 2026;44:827.
    PubMed         Abstract available

  81. SULEJA A, Bret D, Miszczyk M, Dong W, et al
    Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysis.
    World J Urol. 2026;44:810.
    PubMed         Abstract available

  82. ABUSHAMMA F, Abdalrazeq H, Hajjeh O, Algharaba S, et al
    Urinary biomarker-guided surveillance versus standard cystoscopic surveillance for non-muscle-invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trials.
    World J Urol. 2026;44:811.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum